Completed PHASE1 INTERVENTIONAL 2-arm NCT00834639

Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

A Relative Bioavailability Study of 500 mg Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

Sponsor: Teva Pharmaceuticals USA

Conditions Healthy

Interventions Depakote® divalproex sodium

Updated 7 times since 2017 Last updated: Aug 14, 2009 Started: Sep 30, 2003 Primary completion: Sep 30, 2003 Completion: Sep 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Teva Pharmaceuticals USA leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Pharmaceuticals USA

Data source: Teva Pharmaceuticals USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fargo, United States